scispace - formally typeset
Open AccessJournal ArticleDOI

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

TLDR
HDRACi treatment represents an effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors and inhibited genes regulating hematopoietic stem cell maintenance and survival.
About
This article is published in Cancer Cell.The article was published on 2010-05-18 and is currently open access. It has received 250 citations till now. The article focuses on the topics: Chronic myelogenous leukemia & Imatinib mesylate.

read more

Citations
More filters
Journal ArticleDOI

Clonal evolution in cancer

TL;DR: The inherently Darwinian character of cancer is the primary reason for this therapeutic failure, but it may also hold the key to more effective control.
Journal ArticleDOI

Cancer epigenetics reaches mainstream oncology

TL;DR: The discovery of mutations in the epigenetic machinery and the approval of the first epigenetic drugs for the treatment of subtypes of leukemias and lymphomas has been an eye-opener for many biomedical scientists and clinicians.
Journal ArticleDOI

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.

TL;DR: This review highlights the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs and provides better therapeutic rationales to accompany novel anticancer therapeutics.
Journal ArticleDOI

Cancer Stem Cells: Basic Concepts and Therapeutic Implications

TL;DR: This review discusses how the concept of CSCs has been defined, what assays are currently used to define the functional properties of C SCs, what intrinsic and extrinsic mechanisms regulate CSC functions, how plastic CSC's are, and the importance of epithelial-to-mesenchymal transition in conferring CSC properties.
Journal ArticleDOI

Stem cell fate in cancer growth, progression and therapy resistance

TL;DR: Evidence showing that activation of stem cell programmes in cancers can lead to progression, therapy resistance and metastatic growth and that targeting these attributes may enable better control over a difficult disease is considered.
References
More filters
Journal ArticleDOI

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

TL;DR: A workshop was convened by the AACR to discuss the rapidly emerging cancer stem cell model for tumor development and progression, and participants were charged with evaluating data suggesting that cancers develop from a small subset of cells with self-renewal properties analogous to organ regeneration.
Journal ArticleDOI

Anticancer activities of histone deacetylase inhibitors.

TL;DR: Recent advances in the understanding of the molecular events that underlie the anticancer effects of HDAC inhibitors are summarized and how such information could be used in optimizing the development and application of these agents in the clinic, either as monotherapies or in combination with other anticancer drugs are discussed.
Related Papers (5)